title: [Results of multimodality therapy for unresectable primary liver cancer].
abstract: OBJECTIVE
  To investigate the therapeutic measures for unresectable primary liver cancer (PLC).
  
  
  METHODS
  The date of 312 unresectable primary liver cancer patients treated from January 1991 to March 2003 were retrospectively analyzed.
  
  
  RESULTS
  Of these 312 patients, 73 were treated by cryosurgery-based combined modality therapy, 239 were treated by a TACE-oriented combined modality therapy. 289 patients except 23 were followed for a period of 2 to 156 months. The overall 1-,3- and 5-year survival rate in this series was 74. 0% , 34. 0% and 16. 7% , respectively. The 1-,3-and 5-year survival rate in the cryosurgery group was 64. 4% , 38. 4% and 27. 4% , respectively. The 1-, 3- and 5-year survival rate in the TACE group was 75. 1% , 29. 0% and 10. 0%, respectively.
  
  
  CONCLUSIONS
  Treatment for the unresectable primary liver cancer should be individualized and combined with suitable therapeutic modalities.
authors.affiliation: Department of General Surgery, Beijing Union Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100032, China. shuguang9@btmail.net.cn
authors.forename: Shu-guang
authors.initials: SG
authors.lastname: Chen
authors.forename: Shuang-min
authors.initials: SM
authors.lastname: Zhang
authors.forename: Hai-tao
authors.initials: HT
authors.lastname: Zhao
authors.forename: Ning
authors.initials: N
authors.lastname: Zhang
authors.forename: Kai
authors.initials: K
authors.lastname: Han
authors.forename: Shao-bin
authors.initials: SB
authors.lastname: Wang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Qu
authors.forename: Xue
authors.initials: X
authors.lastname: Wei
authors.forename: Jingan
authors.initials: J
authors.lastname: Rui
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D003131:Combined Modality Therapy; D003452:Cryosurgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000628:therapy; D008113:Liver Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D016019:Survival Analysis